Al Mansor Essa, Adamiak Anna, Asmis Timothy
Medical Oncology Department, The Ottawa Hospital, Ottawa, ON, Canada.
Internal Medicine Department, King Abdulaziz Hospital, Al Ahsa, Saudi Arabia.
Case Rep Oncol. 2024 Jan 5;17(1):49-55. doi: 10.1159/000535099. eCollection 2024 Jan-Dec.
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder brought on by pathogenic mutations in the tumor suppressor gene. LFS is characterized by a high lifetime risk of developing various cancers at a relatively young age.
We are presenting a 48-year-old male with a diagnosis of LFS that was confirmed by a genetic test triggered by the patient's son's diagnosis of LFS and leukemia. The patient's main symptoms were abdominal pain and weight loss. The patient was diagnosed with two synchronous primary tumors: first, a metastatic gastric invasive adenocarcinoma that is microsatellite instability (MSI) -high; and second, a low grade (G1) (non-function) well-differentiated pancreatic neuroendocrine tumor. These cancers are not the usual type associated with LFS. After eight cycles of chemo-immunotherapy in the form of FOLFOX-Nivolumab, our radiological assessment showed significant response in the metastatic gastric adenocarcinoma and stable disease in pancreatic neuroendocrine tumor. The patient remains on single agent Nivolumab and has had stable disease for the last 12 months.
Gastric cancer and neuroendocrine tumors are not usually associated with LFS. This case illustrates a rare clinical presentation of multiple malignancies in LFS patients.
李-佛美尼综合征(LFS)是一种由肿瘤抑制基因的致病性突变引起的罕见常染色体显性疾病。LFS的特征是在相对年轻时患各种癌症的终生风险较高。
我们报告一名48岁男性,经基因检测确诊为LFS,该检测由患者儿子被诊断为LFS和白血病引发。患者的主要症状为腹痛和体重减轻。患者被诊断出患有两种同步原发性肿瘤:第一种是微卫星高度不稳定(MSI)的转移性胃浸润性腺癌;第二种是低级别(G1)(无功能)高分化胰腺神经内分泌肿瘤。这些癌症并非通常与LFS相关的类型。在以FOLFOX-纳武单抗形式进行了8个周期的化疗免疫治疗后,我们的影像学评估显示转移性胃腺癌有显著反应,胰腺神经内分泌肿瘤病情稳定。患者继续使用单药纳武单抗,在过去12个月病情一直稳定。
胃癌和神经内分泌肿瘤通常与LFS无关。本病例说明了LFS患者中多种恶性肿瘤的罕见临床表现。